Daniel Allen Gold Sells 917,282 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 917,282 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $23.04, for a total value of $21,134,177.28. Following the sale, the director owned 17,130,445 shares in the company, valued at $394,685,452.80. The trade was a 5.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Wednesday, December 17th, Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock. The stock was sold at an average price of $23.07, for a total value of $17,933,049.24.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.23, for a total value of $26,299,000.00.

Roivant Sciences Trading Up 2.8%

NASDAQ ROIV opened at $22.41 on Friday. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $23.47. The stock has a 50 day moving average of $20.00 and a 200-day moving average of $15.07. The company has a market cap of $15.59 billion, a PE ratio of -40.02 and a beta of 1.22.

Institutional Trading of Roivant Sciences

Several institutional investors have recently added to or reduced their stakes in ROIV. Jones Financial Companies Lllp grew its holdings in Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares in the last quarter. Allworth Financial LP boosted its position in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Bessemer Group Inc. boosted its position in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. CWM LLC grew its stake in shares of Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after acquiring an additional 920 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd increased its position in Roivant Sciences by 75.8% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock worth $67,000 after acquiring an additional 1,900 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ROIV shares. Citigroup upped their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Roivant Sciences in a research report on Thursday. Leerink Partners lifted their target price on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday. The Goldman Sachs Group increased their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.19.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.